[SCHEDULE 13G] Lexeo Therapeutics, Inc. SEC Filing
Vestal Point Capital, LP and Ryan Wilder report beneficial ownership of 3,228,161 shares of Lexeo Therapeutics, Inc. (ticker LXEO), representing 6.0% of the outstanding common stock. The percentage is calculated using an aggregate share count of 53,987,117 shares, reflecting 33,196,997 shares reported as of May 9, 2025, plus 20,790,120 shares issued in a May 27, 2025 private placement. Vestal Point acts as investment manager to a fund and a managed account that hold the shares; Mr. Wilder is the investment manager鈥檚 CIO and managing partner and signed the filing. The filing states the shares were acquired and are held in the ordinary course of business and not to influence control.
Vestal Point Capital, LP e Ryan Wilder dichiarano la titolarit脿 effettiva di 3.228.161 azioni di Lexeo Therapeutics, Inc. (ticker LXEO), pari al 6,0% del capitale sociale in circolazione. La percentuale 猫 calcolata su un totale aggregato di 53.987.117 azioni, che comprende 33.196.997 azioni segnalate al 9 maggio 2025 e 20.790.120 azioni emesse in un collocamento privato del 27 maggio 2025. Vestal Point opera come gestore degli investimenti per un fondo e un conto gestito che detengono le azioni; il sig. Wilder 猫 CIO e partner dirigente del gestore degli investimenti ed ha firmato la comunicazione. Nella dichiarazione si afferma che le azioni sono state acquisite e sono detenute nell'ordinario svolgimento dell'attivit脿 e non con l'intento di influenzare il controllo.
Vestal Point Capital, LP y Ryan Wilder informan de la propiedad beneficiaria de 3.228.161 acciones de Lexeo Therapeutics, Inc. (s铆mbolo LXEO), que representan el 6,0% del capital social en circulaci贸n. El porcentaje se calcula sobre un total agregado de 53.987.117 acciones, que refleja 33.196.997 acciones reportadas al 9 de mayo de 2025 m谩s 20.790.120 acciones emitidas en una colocaci贸n privada el 27 de mayo de 2025. Vestal Point act煤a como gestor de inversiones de un fondo y una cuenta gestionada que poseen las acciones; el Sr. Wilder es el CIO y socio gerente del gestor de inversiones y firm贸 la presentaci贸n. La declaraci贸n indica que las acciones se adquirieron y se mantienen en el curso ordinario del negocio y no para influir en el control.
Vestal Point Capital, LP鞕� Ryan Wilder電� Lexeo Therapeutics, Inc.(韹办护 LXEO)鞚� 鞁れ唽鞙犾＜搿滌劀 3,228,161欤茧ゼ 氤挫湢頃橁碃 鞛堨潓鞚� 氤搓碃頃橂┌, 鞚措姅 氚滍枆 氤错喌欤� 齑濎垬鞚� 6.0%鞐� 頃措嫻頃╇媹雼�. 頃措嫻 牍勳湪鞚� 齑� 53,987,117欤茧ゼ 旮办鞙茧 靷办爼霅橂┌, 鞐赴鞐愲姅 2025雲� 5鞗� 9鞚检瀽搿� 鞁犼碃霅� 33,196,997欤检檧 2025雲� 5鞗� 27鞚� 靷氚办爼鞙茧 氚滍枆霅� 20,790,120欤缄皜 韽暔霅╇媹雼�. Vestal Point電� 頃措嫻 欤检嫕鞚� 氤挫湢頃� 韼�霌滌檧 鞖挫毄瓿勳鞚� 韴瀽毵る媹鞝�搿滌劀 頇滊彊頃橂┌, Wilder 鞌姅 攴� 韴瀽毵る媹鞝�鞚� CIO 瓴� 毵る媹歆� 韺岉姼雱堧靹� 鞁犼碃靹滌棎 靹滊獏頄堨姷雼堧嫟. 鞁犼碃靹滌棎電� 欤检嫕鞚� 鞓侅梾鞚� 韱奠儊鞝侅澑 瓿检爼鞐愳劀 旆摑路氤挫湢霅橃棃鞙茧┌ 歆�氚瓣秾鞐� 鞓來枼鞚� 氙胳箻旮� 鞙勴暅 瓴冹澊 鞎勲嫎鞚� 氇呾嫓頃橁碃 鞛堨姷雼堧嫟.
Vestal Point Capital, LP et Ryan Wilder d茅clarent la propri茅t茅 b茅n茅ficiaire de 3 228 161 actions de Lexeo Therapeutics, Inc. (symbole LXEO), repr茅sentant 6,0% du capital social en circulation. Le pourcentage est calcul茅 sur un total agr茅g茅 de 53 987 117 actions, comprenant 33 196 997 actions d茅clar茅es au 9 mai 2025 et 20 790 120 actions 茅mises lors d鈥檜n placement priv茅 le 27 mai 2025. Vestal Point agit en tant que gestionnaire d鈥檌nvestissements pour un fonds et un compte g茅r茅 qui d茅tiennent les actions ; M. Wilder est le CIO et associ茅 directeur du gestionnaire d鈥檌nvestissements et a sign茅 le d茅p么t. Le document indique que les actions ont 茅t茅 acquises et sont d茅tenues dans le cours normal des affaires et non dans le but d鈥檌nfluencer le contr么le.
Vestal Point Capital, LP und Ryan Wilder melden die wirtschaftliche Eigent眉merschaft von 3.228.161 Aktien der Lexeo Therapeutics, Inc. (Ticker LXEO), was 6,0% des ausstehenden Stammkapitals entspricht. Der Prozentsatz basiert auf einer aggregierten Aktienanzahl von 53.987.117 Aktien, bestehend aus 33.196.997 Aktien, die zum 9. Mai 2025 gemeldet wurden, zuz眉glich 20.790.120 Aktien, die in einer Privatplatzierung am 27. Mai 2025 ausgegeben wurden. Vestal Point fungiert als Investmentmanager eines Fonds und eines verwalteten Kontos, die die Aktien halten; Herr Wilder ist CIO und gesch盲ftsf眉hrender Partner des Investmentmanagers und hat die Meldung unterzeichnet. In der Meldung hei脽t es, die Aktien seien im gew枚hnlichen Gesch盲ftsverlauf erworben und gehalten worden und dienten nicht dazu, die Kontrolle zu beeinflussen.
- Material disclosure of ownership above the 5% reporting threshold (3,228,161 shares, 6.0%)
- Clear identification of the filing parties: Vestal Point Capital, LP and Ryan Wilder with business addresses and roles
- Calculation basis provided for percent of class using aggregate outstanding shares and noting the May 27, 2025 private placement
- None.
Insights
TL;DR: A 6.0% stake by an investment manager signals a meaningful minority position but the filing asserts passive intent.
The report discloses a position of 3,228,161 shares equal to 6.0% of Lexeo's outstanding common stock based on 53,987,117 shares. As an institutional investor filing under Schedule 13G, Vestal Point is identifying a material economic stake while certifying the holdings are in the ordinary course of business and not for control. This is a material ownership disclosure because it exceeds the 5% threshold that requires public reporting; however, the filing does not indicate activist intentions, additional transactions, or planned changes to board or capital structure.
TL;DR: Ownership exceeds the 5% reporting threshold but the certifying language denotes a passive, non-control purpose.
The filing names Vestal Point Capital, LP as investment manager and Ryan Wilder as the individual associated with the position. The Schedule 13G classification and the signed certification state the shares are held in the ordinary course of business and not to influence control, which aligns with passive investor treatment under the Exchange Act. From a governance perspective, the disclosure provides transparency on significant ownership and the responsible signatory but does not signal any governance actions or nominations.
Vestal Point Capital, LP e Ryan Wilder dichiarano la titolarit脿 effettiva di 3.228.161 azioni di Lexeo Therapeutics, Inc. (ticker LXEO), pari al 6,0% del capitale sociale in circolazione. La percentuale 猫 calcolata su un totale aggregato di 53.987.117 azioni, che comprende 33.196.997 azioni segnalate al 9 maggio 2025 e 20.790.120 azioni emesse in un collocamento privato del 27 maggio 2025. Vestal Point opera come gestore degli investimenti per un fondo e un conto gestito che detengono le azioni; il sig. Wilder 猫 CIO e partner dirigente del gestore degli investimenti ed ha firmato la comunicazione. Nella dichiarazione si afferma che le azioni sono state acquisite e sono detenute nell'ordinario svolgimento dell'attivit脿 e non con l'intento di influenzare il controllo.
Vestal Point Capital, LP y Ryan Wilder informan de la propiedad beneficiaria de 3.228.161 acciones de Lexeo Therapeutics, Inc. (s铆mbolo LXEO), que representan el 6,0% del capital social en circulaci贸n. El porcentaje se calcula sobre un total agregado de 53.987.117 acciones, que refleja 33.196.997 acciones reportadas al 9 de mayo de 2025 m谩s 20.790.120 acciones emitidas en una colocaci贸n privada el 27 de mayo de 2025. Vestal Point act煤a como gestor de inversiones de un fondo y una cuenta gestionada que poseen las acciones; el Sr. Wilder es el CIO y socio gerente del gestor de inversiones y firm贸 la presentaci贸n. La declaraci贸n indica que las acciones se adquirieron y se mantienen en el curso ordinario del negocio y no para influir en el control.
Vestal Point Capital, LP鞕� Ryan Wilder電� Lexeo Therapeutics, Inc.(韹办护 LXEO)鞚� 鞁れ唽鞙犾＜搿滌劀 3,228,161欤茧ゼ 氤挫湢頃橁碃 鞛堨潓鞚� 氤搓碃頃橂┌, 鞚措姅 氚滍枆 氤错喌欤� 齑濎垬鞚� 6.0%鞐� 頃措嫻頃╇媹雼�. 頃措嫻 牍勳湪鞚� 齑� 53,987,117欤茧ゼ 旮办鞙茧 靷办爼霅橂┌, 鞐赴鞐愲姅 2025雲� 5鞗� 9鞚检瀽搿� 鞁犼碃霅� 33,196,997欤检檧 2025雲� 5鞗� 27鞚� 靷氚办爼鞙茧 氚滍枆霅� 20,790,120欤缄皜 韽暔霅╇媹雼�. Vestal Point電� 頃措嫻 欤检嫕鞚� 氤挫湢頃� 韼�霌滌檧 鞖挫毄瓿勳鞚� 韴瀽毵る媹鞝�搿滌劀 頇滊彊頃橂┌, Wilder 鞌姅 攴� 韴瀽毵る媹鞝�鞚� CIO 瓴� 毵る媹歆� 韺岉姼雱堧靹� 鞁犼碃靹滌棎 靹滊獏頄堨姷雼堧嫟. 鞁犼碃靹滌棎電� 欤检嫕鞚� 鞓侅梾鞚� 韱奠儊鞝侅澑 瓿检爼鞐愳劀 旆摑路氤挫湢霅橃棃鞙茧┌ 歆�氚瓣秾鞐� 鞓來枼鞚� 氙胳箻旮� 鞙勴暅 瓴冹澊 鞎勲嫎鞚� 氇呾嫓頃橁碃 鞛堨姷雼堧嫟.
Vestal Point Capital, LP et Ryan Wilder d茅clarent la propri茅t茅 b茅n茅ficiaire de 3 228 161 actions de Lexeo Therapeutics, Inc. (symbole LXEO), repr茅sentant 6,0% du capital social en circulation. Le pourcentage est calcul茅 sur un total agr茅g茅 de 53 987 117 actions, comprenant 33 196 997 actions d茅clar茅es au 9 mai 2025 et 20 790 120 actions 茅mises lors d鈥檜n placement priv茅 le 27 mai 2025. Vestal Point agit en tant que gestionnaire d鈥檌nvestissements pour un fonds et un compte g茅r茅 qui d茅tiennent les actions ; M. Wilder est le CIO et associ茅 directeur du gestionnaire d鈥檌nvestissements et a sign茅 le d茅p么t. Le document indique que les actions ont 茅t茅 acquises et sont d茅tenues dans le cours normal des affaires et non dans le but d鈥檌nfluencer le contr么le.
Vestal Point Capital, LP und Ryan Wilder melden die wirtschaftliche Eigent眉merschaft von 3.228.161 Aktien der Lexeo Therapeutics, Inc. (Ticker LXEO), was 6,0% des ausstehenden Stammkapitals entspricht. Der Prozentsatz basiert auf einer aggregierten Aktienanzahl von 53.987.117 Aktien, bestehend aus 33.196.997 Aktien, die zum 9. Mai 2025 gemeldet wurden, zuz眉glich 20.790.120 Aktien, die in einer Privatplatzierung am 27. Mai 2025 ausgegeben wurden. Vestal Point fungiert als Investmentmanager eines Fonds und eines verwalteten Kontos, die die Aktien halten; Herr Wilder ist CIO und gesch盲ftsf眉hrender Partner des Investmentmanagers und hat die Meldung unterzeichnet. In der Meldung hei脽t es, die Aktien seien im gew枚hnlichen Gesch盲ftsverlauf erworben und gehalten worden und dienten nicht dazu, die Kontrolle zu beeinflussen.
FAQ
How many Lexeo Therapeutics (LXEO) shares does Vestal Point Capital report owning?
What percentage of LXEO does the reported stake represent?
Who filed the Schedule 13G for LXEO and who signed it?
Does the filing state the shares were acquired to influence control of Lexeo (LXEO)?
What share count did the filing use to calculate the 6.0% ownership?
